MIRA

Mira Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.370

-0.06(-4.196%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.461007

Open

1.430

VWAP

1.40

Vol

375.92K

Mkt Cap

23.18M

Low

1.370

Amount

525.07K

EV/EBITDA(TTM)

Total Shares

14.78M

22.99M

EV/OCF(TTM)

P/S(TTM)

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial. It is for patients suffering from neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD). MIRA-55 is a preclinical-stage investigational drug designed to support cognitive function and enhance memory. It is for the treatment of patients experiencing cognitive decline, including those with early neurodegenerative conditions.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.085

-39.29%

-0.085

-39.29%

-0.130

+18.18%

Estimates Revision

The market is revising No Change the revenue expectations for MIRA Pharmaceuticals, Inc. (MIRA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 18.10%.

EPS Estimates for FY2025

Revise Downward

-12.5%

In Past 3 Month

Stock Price

Go Up

+18.10%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Mira Pharmaceuticals Inc (MIRA.O) is -4.14, compared to its 5-year average forward P/E of -3.57. For a more detailed relative valuation and DCF analysis to assess Mira Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.57

Current PE

-4.14

Overvalued PE

0.17

Undervalued PE

-7.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.20

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.13

Undervalued EV/EBITDA

-2.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

0.00

Total Revenue

FY2025Q1

YoY :

+2.09%

-1.81M

Operating Profit

FY2025Q1

YoY :

+3.84%

-1.78M

Net Income after Tax

FY2025Q1

YoY :

+22.22%

-0.11

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

133.7K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

134.7K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

133.7K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

MIRA News & Events

Events Timeline

2025-07-30 (ET)

2025-07-30

07:41:08

Mira Pharmaceuticals reports preclinical data on topical Ketamir-2

2025-07-29 (ET)

2025-07-29

07:43:22

Mira Pharmaceuticals announces FDA clearance of IND for Ketamir-2

2025-07-11 (ET)

2025-07-11

08:14:05

Mira Pharmaceuticals reports preclinical data on SKNY-1 candidate

News

4.5

07-03Benzinga

US Stocks Likely To Open Higher As Trump Announces Vietnam Trade Deal: S&P 500's Golden Cross 'Reason To Expect Better Than Average Returns,' Says Expert

2.0

07-03Benzinga

Why Datadog Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

9.0

07-03Benzinga

MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours